神经生物标记市场机会、成长动力、产业趋势分析及 2025 年至 2034 年预测

2024 年，全球神经生物标记市场估值为 95 亿美元，预计 2025 年至 2034 年间将以 10.9% 的年复合成长率(CAGR) 增长。的盛行率不断上升，推动市场成长的关键因素。神经系统疾病的增加主要归因于人口老化，阿兹海默症在老年人中变得越来越常见。

这些疾病的激增刺激了对个人化医疗的需求，因为量身定制的治疗可以为患者带来更好的结果。基因组学、蛋白质组学和成像技术的进步也在神经系统疾病的早期检测和诊断中发挥关键作用。识别大脑或血液中特定蛋白质、基因或代谢物的生物标记物显着提高了诊断准确性，使医疗保健专业人员能够提供及时有效的治疗。

神经生物标记是评估各种神经系统疾病的存在和进展的关键指标。这些生物标记可以是与阿兹海默症、帕金森氏症、多发性硬化症和自闭症谱系障碍等疾病相关的分子、基因或其他物质。市场按产品类型分为蛋白质体学、基因组学、代谢组学、影像和其他生物标记。其中，在液相层析质谱 (LC-MS/MS) 和多重检测等技术进步的推动下，蛋白质体生物标记细分市场在 2024 年占据市场主导地位，占 31 亿美元。

这些创新提高了蛋白质体学测试的灵敏度和可靠性，从而可以更早地检测并更好地管理神经系统疾病。此外，对精准医学的日益关注预计将增加临床环境和药物开发中对蛋白质组生物标记的需求。

按疾病类型划分，阿兹海默症在 2024 年占据最大市场份额，达到 45.5%，反映出对早期诊断解决方案的迫切需求。基于血液的生物标记已成为传统脑脊髓液测试的侵入性较小且更具成本效益的替代方案，进一步推动了市场成长。

以2024 年的最终用途计算，医院和诊所领域在市场中占据主导地位，预计到2034 年将达到110 亿美元。患者的治疗效果。政府支持、研究资助以及与私人组织的合作也正在加速将生物标记融入常规临床实践。

在北美，美国在 2024 年占据神经生物标记市场的重要份额，价值 37 亿美元。该地区受益于技术进步、对精准医疗的日益关注以及对针对个人遗传和疾病特征的个人化治疗的不断增长的需求。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 神经系统疾病盛行率增加
    • 生物标记研究进展
    • 采用个人化医疗
    • 患者和医疗保健提供者对神经系统疾病的认识不断提高
  • 产业陷阱与挑战
    • 生物标记检测成本高
    • 缺乏标准化
• 成长潜力分析
• 未来市场趋势
• 监管环境
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按产品类型，2021 - 2034 年

• 主要趋势
• 蛋白质体生物标记
• 基因组生物标记
• 代谢组生物标记
• 影像学
• 其他生物标记类型

第 6 章：市场估计与预测：按疾病类型，2021 - 2034 年

• 主要趋势
• 阿兹海默症
• 帕金森氏症
• 自闭症谱系障碍
• 癫痫
• 其他疾病

第 7 章：市场估计与预测：按最终用途，2021 - 2034 年

• 主要趋势
• 医院和诊所
• 研究实验室
• 生物製药公司
• 其他最终用户

第 8 章：市场估计与预测：按地区划分，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 9 章：公司简介

• Abbott Laboratories
• ACOBIOM
• Alseres Pharmaceuticals
• Banyan Biomarkers
• Bio-Rad Laboratories
• DiaGenic ASA
• Johnson & Johnson Services
• Merck KGaA
• QIAGEN
• Quanterix
• Rules-Based Medicine
• Thermo Fisher Scientific

The Global Neurological Biomarkers Market was valued at USD 9.5 billion in 2024 and is expected to grow at a compound annual growth rate (CAGR) of 10.9% between 2025 and 2034. The rising prevalence of neurodegenerative disorders, such as Alzheimer's and Parkinson's disease, is a key factor driving market growth. This increase in neurological conditions is primarily attributed to the aging population, with Alzheimer's disease becoming increasingly common among older adults.

The surge in these disorders has fueled demand for personalized medicine, as tailored treatments can lead to better outcomes for patients. Advancements in genomics, proteomics, and imaging technologies are also playing a pivotal role in the early detection and diagnosis of neurological diseases. Biomarkers that identify specific proteins, genes, or metabolites in the brain or blood have significantly enhanced diagnostic accuracy, enabling healthcare professionals to provide timely and effective treatment.

Neurological biomarkers serve as critical indicators for assessing the presence and progression of various neurological diseases. These biomarkers can be molecules, genes, or other substances linked to conditions such as Alzheimer's, Parkinson's, multiple sclerosis, and autism spectrum disorders. The market is segmented by product type into proteomic, genomic, metabolomic, imaging, and other biomarkers. Among these, the proteomic biomarker segment led the market in 2024, accounting for USD 3.1 billion, driven by advancements in technologies like liquid chromatography-mass spectrometry (LC-MS/MS) and multiplex assays.

These innovations have improved the sensitivity and reliability of proteomic tests, allowing for earlier detection and better management of neurological conditions. Additionally, the growing focus on precision medicine is expected to boost demand for proteomic biomarkers in both clinical settings and drug development.

By disease type, Alzheimer's disease held the largest market share of 45.5% in 2024, reflecting the urgent need for early diagnostic solutions. Blood-based biomarkers have emerged as a less invasive and more cost-effective alternative to traditional cerebrospinal fluid tests, further driving market growth.

The hospitals and clinics segment dominated the market by end use in 2024 and is projected to reach USD 11 billion by 2034. These facilities are increasingly adopting non-invasive biomarker diagnostics, improving patient outcomes through personalized care. Government support, funding for research, and collaborations with private organizations are also accelerating the integration of biomarkers into routine clinical practice.

In North America, the U.S. held a significant share of the neurological biomarkers market in 2024, valued at USD 3.7 billion. The region benefits from technological advancements, increased focus on precision medicine, and a rising demand for personalized therapies tailored to individual genetic and disease profiles.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of neurological disorders
    • 3.2.1.2 Advancement in biomarker research
    • 3.2.1.3 Adoption of personalized medicine
    • 3.2.1.4 Rising awareness among patients and healthcare providers of neurological disorders
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of biomarker testing
    • 3.2.2.2 Lack of standardization
• 3.3 Growth potential analysis
• 3.4 Future market trends
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Proteomic biomarkers
• 5.3 Genomic biomarkers
• 5.4 Metabolomic biomarkers
• 5.5 Imaging
• 5.6 Other biomarker types

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Alzheimer's disease
• 6.3 Parkinson's disease
• 6.4 Autism spectrum disorders
• 6.5 Epilepsy
• 6.6 Other diseases

Chapter 7 Market Estimates and Forecast, By End Use, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Hospitals and clinics
• 7.3 Research laboratories
• 7.4 Biopharmaceutical companies
• 7.5 Other end users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 India
  • 8.4.3 Japan
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Abbott Laboratories
• 9.2 ACOBIOM
• 9.3 Alseres Pharmaceuticals
• 9.4 Banyan Biomarkers
• 9.5 Bio-Rad Laboratories
• 9.6 DiaGenic ASA
• 9.7 Johnson & Johnson Services
• 9.8 Merck KGaA
• 9.9 QIAGEN
• 9.10 Quanterix
• 9.11 Rules-Based Medicine
• 9.12 Thermo Fisher Scientific